JP2016526016A - がんを治療する方法 - Google Patents

がんを治療する方法 Download PDF

Info

Publication number
JP2016526016A
JP2016526016A JP2016512011A JP2016512011A JP2016526016A JP 2016526016 A JP2016526016 A JP 2016526016A JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016526016 A JP2016526016 A JP 2016526016A
Authority
JP
Japan
Prior art keywords
fgfr1
cancer
ecd
fgfr1 ecd
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526016A5 (enExample
Inventor
ジュリー ハンブルトン，
ジュリー ハンブルトン，
モーリーン アール． ブリーム，
モーリーン アール． ブリーム，
モーリス ピー． デヤング，
モーリス ピー． デヤング，
ジェラルディーン フェロン−ブレイディ，
ジェラルディーン フェロン−ブレイディ，
ラケシュ クマール，
ラケシュ クマール，
ローン オッテセン，
ローン オッテセン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2016526016A publication Critical patent/JP2016526016A/ja
Publication of JP2016526016A5 publication Critical patent/JP2016526016A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016512011A 2013-05-01 2014-04-30 がんを治療する方法 Pending JP2016526016A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361818220P 2013-05-01 2013-05-01
US61/818,220 2013-05-01
US201361831029P 2013-06-04 2013-06-04
US61/831,029 2013-06-04
PCT/US2014/036140 WO2014179448A2 (en) 2013-05-01 2014-04-30 Methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2016526016A true JP2016526016A (ja) 2016-09-01
JP2016526016A5 JP2016526016A5 (enExample) 2017-06-15

Family

ID=50928263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512011A Pending JP2016526016A (ja) 2013-05-01 2014-04-30 がんを治療する方法

Country Status (13)

Country Link
US (2) US20160067307A1 (enExample)
EP (1) EP2991669A2 (enExample)
JP (1) JP2016526016A (enExample)
KR (1) KR20160003141A (enExample)
CN (1) CN105188732A (enExample)
AU (1) AU2014259956A1 (enExample)
BR (1) BR112015027607A8 (enExample)
CA (1) CA2908391A1 (enExample)
HK (1) HK1213817A1 (enExample)
MX (1) MX2015015115A (enExample)
RU (1) RU2015150233A (enExample)
SG (1) SG11201508878WA (enExample)
WO (1) WO2014179448A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
PE20160190A1 (es) 2013-08-01 2016-04-28 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
KR20180028524A (ko) * 2015-07-24 2018-03-16 데비오팜 인터네셔날 에스 에이 Fgfr 발현 및 fgfr 억제제에 대한 민감성
BR112018010410A8 (pt) * 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
PL238516B1 (pl) 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
AU2018215794A1 (en) * 2017-02-06 2019-07-25 Fusion Pharmaceuticals Inc. Methods, compositions, and kits for treatment of cancer
WO2018195273A1 (en) * 2017-04-19 2018-10-25 The Corporation Of Mercer University Sam-1 protein, composition and methods of use
CN110621336B (zh) 2017-05-16 2024-05-14 戊瑞治疗有限公司 癌症治疗中抗fgfr2抗体与化学治疗剂的组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525493A (ja) * 2004-12-22 2008-07-17 オキシジーン， インコーポレイテッド 腫瘍増殖および転移を調節する方法
JP2009514879A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
WO2012068032A1 (en) * 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
WO2013074492A1 (en) * 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8481038B2 (en) * 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525493A (ja) * 2004-12-22 2008-07-17 オキシジーン， インコーポレイテッド 腫瘍増殖および転移を調節する方法
JP2009514879A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
WO2012068032A1 (en) * 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
WO2013074492A1 (en) * 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARDING, THOMAS C. ET AL.: "Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Ca", SCIENCE TRANSLATIONAL MEDICINE, vol. 5, no. 178, JPN7018000009, March 2013 (2013-03-01), pages 178 - 39, ISSN: 0003717134 *
PROCEEDINGS:AACR 103RD ANNUAL MEETING 2012, CANCER RESEARCH, vol. 72(8 Supplement), JPN6018051141, April 2012 (2012-04-01), pages 1876, ISSN: 0004083900 *
中島誠ほか: "非小細胞肺がんに対する３ｗｅｅｋｓ−カルボプラチン／パクリタキセル併用療法におけるアプレピタントの有", 医療薬学, vol. 39, no. 5, JPN6018000227, May 2013 (2013-05-01), pages 294 - 303, ISSN: 0004083899 *

Also Published As

Publication number Publication date
AU2014259956A1 (en) 2015-11-12
US20180280470A1 (en) 2018-10-04
WO2014179448A3 (en) 2014-12-24
RU2015150233A (ru) 2017-06-02
BR112015027607A2 (pt) 2017-12-05
KR20160003141A (ko) 2016-01-08
WO2014179448A2 (en) 2014-11-06
CA2908391A1 (en) 2014-11-06
HK1213817A1 (zh) 2016-07-15
MX2015015115A (es) 2016-06-07
BR112015027607A8 (pt) 2018-01-23
EP2991669A2 (en) 2016-03-09
SG11201508878WA (en) 2015-11-27
US20160067307A1 (en) 2016-03-10
CN105188732A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
JP6578318B2 (ja) 癌を治療する方法
JP2016526016A (ja) がんを治療する方法
JP5416221B2 (ja) 癌患者における診断用途のための方法および組成物
JP5606537B2 (ja) 癌患者における診断使用のための方法及び組成物
CN107002119A (zh) 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
JP2019023193A (ja) がんを治療する方法
US20140030257A1 (en) Agtr1 as a marker for bevacizumab combination therapies
JP2018085998A (ja) 癌におけるｅｒｂｂ３変異

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190730